The Journal of Experimental Medicine · 2015 · 115 citations · 48 references
Life SciencesCell BiologyImmunologyCancer ImmunologyCellular ImmunologyInnate ImmunityCell-mediated ImmunityImmune Cell SignalingImmune CheckpointsMast Cell ActivationT Cell ActivationT Cell BiologyAntitumor Immune ActivationFc Epsilon Ri SignalingIge Receptor SignalingIge-mediated ActivationLyn-mediated SignalingMast Cell BiologyMast Cell Signaling PathwaysT-cell Mucin Domain-containing Protein 3
T cell (or transmembrane) immunoglobulin and mucin domain protein 3 (Tim-3) has attracted significant attention as a novel immune checkpoint receptor (ICR) on chronically stimulated, often dysfunctional, T cells. Antibodies to Tim-3 can enhance antiviral and antitumor immune responses. Tim-3 is also constitutively expressed by mast cells, NK cells and specific subsets of macrophages and dendritic cells. There is ample evidence for a positive role for Tim-3 in these latter cell types, which is at odds with the model of Tim-3 as an inhibitory molecule on T cells. At this point, little is known about the molecular mechanisms by which Tim-3 regulates the function of T cells or other cell types. We have focused on defining the effects of Tim-3 ligation on mast cell activation, as these cells constitutively express Tim-3 and are activated through an ITAM-containing receptor for IgE (FcεRI), using signaling pathways analogous to those in T cells. Using a variety of gain- and loss-of-function approaches, we find that Tim-3 acts at a receptor-proximal point to enhance Lyn kinase-dependent signaling pathways that modulate both immediate-phase degranulation and late-phase cytokine production downstream of FcεRI ligation.
48
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Chen Zhu, Ana C. Anderson, Anna Schubart et al. · Nature Immunology · 2005 · 2K citations
A nuclear factor for IL‐6 expression (NF‐IL6) is a member of a C/EBP family.
Shizuo Akira, Hiroshi Isshiki, Takahisa Sugita et al. · The EMBO Journal · 1990 · 1.5K citations · Full text